| [Table_BaseData] 收盘价（元） | 33.50 | | --- | --- | | 近 12 个月最高/最低（元） | 47.50/28.10 | | 总股本（百万股） | 209 | | 流通股本（百万股） | 194 | | 流通股比例（%） | 92.90 | | 总市值（亿元） | 70 | | 流通市值（亿元） | 65 | [公司价格与沪深 Table_Chart] 300 走势比较 可孚医疗（ [Table_StockNameRptType] 301087） 公司点评 产品丰富+渠道多元，收入增长持续稳健 | 投资评级：买入（维持） [Table_Rank] | | --- | | 报告日期： 2025-05-04 | -31% -16% -2% 13% 28% 5/24 8/24 11/24 2/25 可孚医疗 沪深300 [Table_Author] 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：李婵 执业证书号：S0010523120002 邮箱：lichan@hazq.com [Table_CompanyRepo ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady revenue growth with a diverse product range and multiple sales channels, achieving a revenue of 2.983 billion yuan in 2024, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.60% year-on-year [5][9] - The company focuses on core product categories and enhances R&D efficiency, launching over a hundred new products, including innovative solutions for chronic disease management [6] - The online sales channel generated 1.990 billion yuan in revenue, a growth of 8.94% year-on-year, while the offline channel saw a decline of 3.12% [7][8] Financial Performance Summary - In 2024, the company achieved a revenue of 2.983 billion yuan, with a net profit of 312 million yuan and a gross margin of 51.9% [11] - Revenue projections for 2025-2027 are 3.580 billion yuan, 4.333 billion yuan, and 5.236 billion yuan, with corresponding net profits of 414 million yuan, 504 million yuan, and 613 million yuan [9][11] - The expected EPS for 2025-2027 is 1.98 yuan, 2.41 yuan, and 2.93 yuan, with P/E ratios of 17x, 14x, and 11x respectively [9][11]